Targeting metabolic disorders through modulation of gut microbiota

Dr. Banshi Saboo
The last few decades have witnessed a continued surge in the prevalence of metabolic disorders, such as obesity, dyslipidemia, insulin resistance, and diabetes mellitus, which pose a significant public health concern. However, recent evidence from scientific community put forth the pathognomonic role of altered gut microbiota composition and diversity as one of the probable factors in the development and increased global incidence of metabolic disorders, especially obesity and diabetes.

Medico-legal aspects of neurosurgery

Current Issue
Number: 6

Clinical Update

Appraising the efficacy of SR pregabalin over SR gabapentin in management of neuropathic pain
Gabapentin (GP) and pregabalin (PB), derivatives of the inhibitory neurotransmitter ?-aminobutyric acid (GABA) are structurally related compounds. As a successor of gabapentin, pregabalin is a favorable drug for the treatment of neuropathic pain, a chronic disease which affects large population thus enforcing the need for long-term treatment.

Other review articles:

Tech Update

OtoSet: An automatic ear cleaning device